Facebook
Twitter
LinkedIn
Forward
Inaugural Houston Methodist Neal Cancer Center GI Oncology Symposium - December 6, 2024
In-Person and Virtual attendance options are available.
Presented by the Houston Methodist Dr. Mary and Ron Neal Cancer Center
This symposium will delve into the latest developments in managing gastrointestinal cancers. It will feature expert presentations on advancements in immunotherapy, molecular diagnostics, targeted therapies and new surgical techniques, . Participants will also explore key trends in transplant oncology and the role of precision medicine. Each session will offer insights into disease pathogenesis, risk factors, prevention strategies, and innovative treatments, including discussions on minimally invasive procedures, enhanced imaging, and blood-based biomarkers. The symposium will emphasize how these advancements improve patient outcomes and provide a comprehensive review of current and emerging management strategies for various gastrointestinal cancers.
FEES
| REGISTRATION TYPE | FEE |
|---|---|
| Houston Methodist Employees | Complimentary |
| Physician (Private physician located within the Greater Houston Area)* | $185 |
| Physician (Private physician located outside the Greater Houston Area) | Complimentary |
| Research Scientist | Complimentary |
| Allied Health Care Professional / All Others | Complimentary |
| Resident / Fellow / Student | Complimentary |
* In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.
Target Audience
This symposium is designed for physician scientists, practicing oncologists, hepatologists, transplant surgeons, physician assistants, advanced nurse practitioners, oncology nurses, gastroenterologists, residents, fellows, medical students, allied health care professionals, and clinical research associates. Attendees involved in hepatobiliary, pancreatic, neuroendocrine, colorectal, esophageal, and gastric cancer care will find valuable insights for advancing their practice and improving patient care.
Learning Objectives
At the conclusion of this activity, the learner should be able to:
- Describe the epidemiology, risk factors, and prevention strategies for gastrointestinal cancers.
- Review the pathogenesis, surveillance modalities, and underuse of screening for hepatocellular carcinoma (HCC), focusing on blood-based biomarkers and management of pre-liver cancer diseases.
- Evaluate transplant-bridging approaches and the role of immunotherapy in both resectable and advanced hepatocellular carcinoma, as well as new developments in treating advanced cholangiocarcinoma.
- Assess updates on operative strategies for early-stage hepatobiliary cancers and transplant oncology for hilar and intrahepatic cholangiocarcinoma.
- Explain the latest advancements in molecular diagnostics, operative and perioperative approaches, and targeted therapies for pancreatic adenocarcinoma, low-/intermediate-grade neuroendocrine carcinoma, and colorectal cancers.
- Discuss advancements in multidisciplinary approaches for managing esophageal and gastric cancers, as well as the role of precision medicine in unresectable gastrointestinal malignancies
TIME | PRESENTATION |
7:40 AM –8:00 AM | Registration |
8:00 AM –8:30 AM | Breakfast |
8:30 AM – 8:35 AM |
Welcome and Introduction |
8:35 AM –8:40 AM | Session 1A: Hepatobiliary Cancer |
8:40 AM –8:50 AM | Worldwide Epidemiology and United States Burden of Liver Cancers: Risk Factors and Prevention |
8:50 AM –9:00 AM | Pathogenesis and Surveillance Modalities of Hepatobiliary Cancer |
9:00 AM –9:10 AM | Current Status of Pre-Liver Cancer Diseases: Management and Future Directions |
9:10 AM –9:20 AM | Underuse and interventions of Hepatocellular Carcinoma screening and Blood-based HCC biomarkers |
09:20 AM –9:35 AM | Panel Discussion |
09:35 AM –09:40 AM | Session 1B: Hepatobiliary Cancer |
9:40 AM – 9:50 AM | Transplant-Bridging Approaches in Hepatocellular Carcinoma |
9:50 AM – 10:00 AM | New Frontiers for Immunotherapy in Patients with Advanced and Resectable Hepatocellular Carcinoma |
10:00 AM – 10:10 AM | Current and Emerging Management in Advanced Cholangiocarcinoma |
10:10 AM – 10:20 AM | Updates on Operative Approaches in Early-Stage Hepatobiliary Cancer |
10:20 AM – 10:30 AM | Transplant oncology for Hilar and Intrahepatic Cholangiocarcinoma: Updates and Future Directions |
10:30 AM –10:45 AM | Panel Discussion |
10:45 AM –10:50 AM | Session 2: Pancreatic & Neuroendocrine Cancer |
10:50 AM – 11:00 AM | Updates on Molecular Diagnostics |
11:00 AM – 11:10 AM | Updates on Operative and Perioperative Approaches in Pancreatic Adenocarcinoma |
11:10 AM – 11:20 AM | Targeted Therapy Developments in Advanced-Stage Pancreatic Adenocarcinoma |
11:20 AM – 11:30 AM | Updates in the Management of Low-/Intermediate-Grade Neuroendocrine Carcinoma |
11:30 AM – 11:45 AM
|
Panel Discussion |
11:45 AM – 12:15 PM | Keynote: Integrating Immunotherapy into the Neoadjuvant Space in Gastrointestinal Malignancies: A Shifting Paradigm |
12:15 PM – 12:20 PM |
Session 3: Colorectal Cancer |
12:20 PM – 12:30 PM | Updates in the Management of Colorectal Liver Metastases |
12:30 PM – 12:40 PM | Advancement in Surgical Management in Colorectal Cancer |
12:40 PM – 12:50 PM | Immunotherapy Developments in Colorectal Cancer, MSI-H |
12:50 PM –01:00 PM | Immunotherapy Developments in Colorectal Cancer, MSS |
01:00 PM – 01:10 PM | Precision Medicine Developments in Colorectal Cancer |
01:10 PM – 01:25 PM
|
Panel Discussion
|
01:25 PM – 02:25 PM | Networking Reception/Lunch |
02:25 PM – 02:030 PM |
Session 4: Esophageal and Gastric Cancer |
02:30 PM – 02:40 PM | Advances in Multidisciplinary Approaches in Resectable Gastric/Esophageal Cancer |
02:40 PM – 02:50 PM | Immunotherapy Advancements and Predictive Markers in Unresectable Gastroesophageal Adenocarcinoma |
02:50 PM – 03:00 PM | Precision Medicine Advancements in Unresectable Gastroesophageal Adenocarcinoma |
03:00 PM – 03:10 PM |
Panel Discussion |
03:10 PM – 03:15 PM | Concluding Remarks |
LIVE (in-person attendance) will be held in the Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030.
Virtual information will be provided to registered learners at a later date.
| CHAIR |
| Maen Abdelrahim, MD, PhD, B Pharm |
Section Chief of Gastrointestinal Medical Oncology |
Available Credit
- 5.25 AMA PRA Category 1 Credit™
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Houston Methodist designates this Live activity for a maximum of 5.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 5.25 Attendance
Interested in exhibiting or sponsoring? Contact us for more information.
Price
FEES
| REGISTRATION TYPE | FEE |
|---|---|
| Houston Methodist Employees | Complimentary |
| Physician (Private physician located within the Greater Houston Area)* | $170 |
| Physician (Private physician located outside the Greater Houston Area) | Complimentary |
| Research Scientist | Complimentary |
| Allied Health Care Professional / All Others | Complimentary |
| Resident / Fellow / Student | Complimentary |
* In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.